Pierre Langlade-Demoyan

Title: Pierre Langlade-Demoyan: Innovator in Immunogenic Peptides

Introduction

Pierre Langlade-Demoyan is a notable inventor based in Paris, France. He has made significant contributions to the field of immunology, particularly in the development of therapeutic vaccines. With a total of 2 patents, his work focuses on optimizing immunogenic peptides for the treatment of leukemia.

Latest Patents

One of Langlade-Demoyan's latest patents is titled "Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof." This invention involves the optimization of the wild R9M peptide, which is derived from the human TEL/AML1 fusion protein. The patent details the use of these mutated immunogenic peptides for therapeutic and preventive vaccination against leukemia in humans. It also encompasses polynucleotides coding for these peptides, cellular expression vectors, and antibodies that can bind to the peptides or polynucleotides. The invention aims to prepare vaccines and anti-tumoral medicines, as well as to stimulate the immune response in both in vitro and in vivo settings.

Career Highlights

Throughout his career, Langlade-Demoyan has worked with prestigious institutions such as Institut Pasteur and Assistance Publique-Hôpitaux de Paris. His research has significantly advanced the understanding of immunogenic peptides and their applications in cancer treatment.

Collaborations

Some of his notable coworkers include Pierre Rohrlich and Patricia Yotnda. Their collaborative efforts have contributed to the success of various research projects in the field of immunology.

Conclusion

Pierre Langlade-Demoyan is a distinguished inventor whose work in immunogenic peptides has the potential to revolutionize therapeutic approaches to leukemia. His innovative patents and collaborations highlight his commitment to advancing medical science.